Sonnet BioTherapeutics
SONN
SONN was delisted on the 2nd of December, 2025.
16 hedge funds and large institutions have $2.63M invested in Sonnet BioTherapeutics in 2023 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
1,644% more capital invested
Capital invested by funds: $151K → $2.63M (+$2.48M)
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
45% more funds holding
Funds holding: 11 → 16 (+5)
0.2% more ownership
Funds ownership: 0.01% → 0.21% (+0.2%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$1.62M |
| 2 |
Walleye Capital
New York
|
+$1.53M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.12M |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$875K |
| 5 |
AC
Ayrton Capital
Westport,
Connecticut
|
+$704K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSS
Two Sigma Securities
New York
|
-$20.7K |
| 2 |
HF
HRT Financial
New York
|
-$18K |
| 3 |
Mariner
Overland Park,
Kansas
|
-$16K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.72K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$3.24K |
SONN Hedge Fund Activity: Q1 2023 in Review
16 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Sonnet BioTherapeutics (SONN) for Q1 2023, worth a combined $2.63M — up 1,644% from $151K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new SONN positions and 4 closed out — a net gain of 5 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $1.62M. The largest seller was Two Sigma Securities, exiting entirely with an estimated $20.7K sold.
- 16 institutional investors held Sonnet BioTherapeutics (SONN) as of Q1 2023, up from 11 in Q4 2022.
- Funds reported $2.63M of Sonnet BioTherapeutics stock for Q1 2023, up 1,644% quarter-over-quarter.
- 9 funds opened new Sonnet BioTherapeutics positions in Q1 2023 and 4 closed out, a net change of +5 holders.
- The largest Sonnet BioTherapeutics buyer in Q1 2023 was Anson Funds Management, an estimated $1.62M added.
- The largest Sonnet BioTherapeutics seller in Q1 2023 was Two Sigma Securities, an estimated $20.7K sold.
Based on aggregated 13F filings for Q1 2023.